CROMA-PHARMA GmbH Sustainability Profile
CROMA-PHARMA GmbH, a leading player in the pharmaceutical and medical device industry, is headquartered in Austria (AT) and operates extensively across Europe and beyond. Founded in 2003, the company has established itself as a pioneer in the development and distribution of innovative aesthetic and therapeutic solutions, particularly in the fields of dermal fillers and regenerative medicine. CROMA-PHARMA's core products, including the renowned Princess® line of dermal fillers, are distinguished by their high-quality formulations and commitment to safety. The company’s focus on research and development has led to significant advancements in minimally invasive treatments, positioning it as a trusted name among healthcare professionals. With a strong market presence and a dedication to excellence, CROMA-PHARMA continues to achieve notable milestones in enhancing patient care and aesthetic outcomes.
DitchCarbon Score
How does CROMA-PHARMA GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
CROMA-PHARMA GmbH's score of 65 is higher than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
CROMA-PHARMA GmbH's reported carbon emissions
In 2024, CROMA-PHARMA GmbH reported total carbon emissions of approximately 7,247,000 kg CO2e. This includes Scope 1 emissions of about 937,000 kg CO2e, Scope 2 emissions of approximately 768,000 kg CO2e, and significant Scope 3 emissions totalling around 12,764,000 kg CO2e. The Scope 3 emissions breakdown reveals major contributions from capital goods (about 2,009,000 kg CO2e), business travel (approximately 322,000 kg CO2e), and employee commuting (around 319,000 kg CO2e). Comparatively, in 2023, the company recorded total emissions of about 7,605,000 kg CO2e, with Scope 1 at approximately 963,000 kg CO2e, Scope 2 at around 804,000 kg CO2e, and Scope 3 emissions reaching about 13,434,000 kg CO2e. This indicates a slight reduction in total emissions from 2023 to 2024. CROMA-PHARMA GmbH has set ambitious climate commitments, aiming for net-zero emissions for Scope 1 and Scope 2 by 2035, with a target reduction of 100% from the 2023 baseline. This long-term goal reflects the company's commitment to sustainability and aligns with industry standards for climate action. The emissions data is cascaded from CROMA-PHARMA GmbH as a current subsidiary, ensuring that their climate commitments and performance are in line with broader corporate sustainability initiatives.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 1,081 | 000,000 | 000,000 |
| Scope 2 | 4,516 | 0,000 | 0,000 |
| Scope 3 | 6,452 | 00,000,000 | 00,000,000 |
How Carbon Intensive is CROMA-PHARMA GmbH's Industry?
How Carbon Intensive is CROMA-PHARMA GmbH's Location?
CROMA-PHARMA GmbH's Scope 3 Categories Breakdown
CROMA-PHARMA GmbH's Scope 3 emissions, which decreased by 5% last year and increased significantly since 2022, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Capital Goods" being the largest emissions source at 16% of Scope 3 emissions.
Top Scope 3 Categories
CROMA-PHARMA GmbH's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
CROMA-PHARMA GmbH has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
